NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.
Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.
An official website of the United States government
Here’s how you know
Official websites use .gov
A .gov website belongs to an official government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
Using enantioselective biosensors to evolve asymmetric biocatalysts
Published
Author(s)
d’Oelsnitz Simon, Wantae Kim, Haley Hardtke, Svetlana Ikonomova, Nina Alperovich, Olga Vasilyeva, Michael James, Eric Zigon, Charlie Johnson, Andrew Ellington, Quincey Justman, Michael Springer, Jessie Zhang, Pamela Silver, David Ross
Abstract
Biocatalysts are championed for their exquisite stereochemistry, but slow chromatographic separations necessary to measure enantiomeric excess can bottleneck their development. Prokaryotic transcription factors can address this limitation by transducing enantiomer-specific chemical concentrations into programmable gene expression outputs. We describe a method for high-throughput chiral screening of asymmetric biocatalysts using enantioselective transcription factors. Using growth-coupled massively parallel sequencing, we quantitatively profile the sensitivity, selectivity, and dynamic range of >300,000 transcription factor variants generated by random, site-saturation, and gene shuffling mutagenesis. Ultimately, we identify biosensors that are both highly sensitive (EC50 as low as 2 µmol/L) and selective for enantiomer products and an achiral precursor of an intermediate used to manufacture the licensed pharmaceutical Solifenacin. High-resolution structures reveal how sterics enforce enantioselectivity and charge interactions differentiate the precursor imine from product amines. Finally, we apply our biosensors to invert the enantioselectivity of an imine reductase by screening a large enzyme library using fluorescence activated cell sorting. We demonstrate that enantioselective transcription factors enable rapid screening of asymmetric reactions, which may dramatically accelerate the pace of biocatalyst development for pharmaceutical manufacture.
Citation
Nature Biotechnology
Pub Type
Journals
Keywords
Synthetic biology, living measurement systems, protein engineering
Simon, D.
, Kim, W.
, Hardtke, H.
, Ikonomova, S.
, Alperovich, N.
, Vasilyeva, O.
, James, M.
, Zigon, E.
, Johnson, C.
, Ellington, A.
, Justman, Q.
, Springer, M.
, Zhang, J.
, Silver, P.
and Ross, D.
(2025),
Using enantioselective biosensors to evolve asymmetric biocatalysts, Nature Biotechnology
(Accessed October 15, 2025)